Sona Nanotech has announced a partnership with GE Healthcare Life Sciences to produce a rapid-response test for the Covid-19 coronavirus, which has sent Sona shares up into uncharted territory.
The two companies announced Tuesday that they will jointly complete test development of the Sona Covid-19 Coronavirus rapid response lateral flow test. They will use GE Healthcare’s Fast Flow High Performance Membrane, or FFHP, in production of the test. Halifax-based Sona will retain all commercial rights to the resulting test.
Sona shares, which first traded on the alternative Canadian Securities